The abstract is read at the publisher; the summary is JClub's.
A patient with relapsed multiple myeloma receiving teclistamab developed LCMV meningoencephalitis, and combination antivirals cleared LCMV from CSF and blood within 2 months.
- Why it matters: LCMV is a rare but severe cause of meningoencephalitis in immunocompromised people, yet UK testing has been uncommon for decades and diagnosis is often delayed.
- What they did: After extensive negative workup and empirical antimicrobials failed, metagenomic next-generation sequencing of CSF identified LCMV; treatment used ribavirin, remdesivir, and molnupiravir (with favipiravir dosing guided by therapeutic drug monitoring).
- The result: The patient had sustained neurological improvement, with LCMV clearance from CSF and blood in 2 months and completion of antiviral therapy for 6 months, regaining functional independence.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.